NDA 020379 · Pfizer
Caverject
Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Jul 6, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
145
40 Phase 3, 8 recruiting
FAERS reports
2,865
2,024 serious, 244 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 13, 2024.
CAVERJECT is a prostaglandin E1 agonist indicated • For the treatment of erectile dysfunction ( 1.1 ). • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction ( 1.2 ). 1.1 Erectile Dysfunction CAVERJECT is indicated for the treatment of erectile dysfunction. 1.2 Diagnostic Test CAVERJECT is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Mechanism: Alprostadil (PGE1) is a prostaglandin with a wide variety of pharmacological actions including vasodilation and inhibition of platelet aggregation. Alprostadil induces erection by relaxation of trabecular smooth muscle and by dilation of cavernosal arteries by binding to its receptors and increasing intracellular cyclic adenosine monophosphate (cAMP) levels via modulation of adenylate cyclase. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism. Alprostadil...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 6, 1995 Original approval · Type 3 - New Dosage Form · priority review
4 products under this application
- CAVERJECT · ALPROSTADIL 0.04MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- CAVERJECT · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- CAVERJECT · ALPROSTADIL 0.005MG/VIAL · INJECTABLE, INJECTION · Discontinued
- CAVERJECT · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.
- Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of LaborPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00308711 · 1,308 participants · Start Apr 2006 · Primary completion Aug 2007
Drug: Misoprostol vaginal insert 100 mcg; Misoprostol vaginal insert 50 mcg and 1 more · For: Cervical Ripening; Labor, Induced
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 52 sites in all
- Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic StrokePivotal-lookingStatus unknown
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT03252626 · 950 participants (planned) · Start Apr 18, 2024 · Primary completion Dec 31, 2024
Drug: Alprostadil; Normal saline · For: Stroke
- Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic ConstipationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01674530 · 909 participants · Start Oct 2012 · Primary completion Jan 2014
Drug: Lubiprostone; Lubiprostone and 1 more · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 93 sites in all
- Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IVPivotal-lookingCompleted
NCT00596752 · 840 participants · Start Mar 2004 · Primary completion May 2013
Drug: Alprostadil · For: Peripheral Arterial Occlusive Disease
Sites: Pilsen, Czechia; Ústí nad Labem, Czechia; Karlsbad, Germany · 78 sites in all
- Evaluation of Clinical Equivalence Between Two Lubiprostone ProductsPivotal-lookingCompleted
Anchen Pharmaceuticals, IncIndustry
NCT01372423 · 808 participants · Start May 2011 · Primary completion Jun 2012
Drug: Lubiprostone; Placebo · For: Chronic Idiopathic Constipation
Sites: Dothan, Alabama; Huntsville, Alabama; Mobile, Alabama · 79 sites in all
- Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening MethodsPivotal-lookingStatus unknown
Hillel Yaffe Medical CenterGovernment (non-federal)
NCT02223949 · 624 participants (planned) · Start Oct 2014 · Primary completion Oct 2016
Drug: PGE1 tablet · For: Obesity; Labor Complications
Sites: Hadera, Israel
- Lubiprostone in Children With Functional ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT02042183 · 606 participants · Start Dec 13, 2013 · Primary completion Jul 27, 2016
Drug: Lubiprostone; Placebo · For: Constipation - Functional
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 117 sites in all
- ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart FailurePivotal-lookingNot yet recruiting
Biopeutics Co., LtdIndustry
NCT00610051 · 600 participants (planned) · Start Oct 2026 · Primary completion Nov 2029
Drug: Alprostadil · For: End Stage Cardiac Failure; HFrEF - Heart Failure With Reduced Ejection Fraction; NYHF Class III-IV
Sites: Vienna, Austria
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective638
- off label use143
- erection increased104
- haemoglobin decreased83
- lymphocyte count decreased79
- pyrexia76
- diarrhoea72
- erectile dysfunction71
- penile pain70
- condition aggravated68
- pain65
- cardiac failure64
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 76 |
| 2005 | 91 |
| 2006 | 126 |
| 2007 | 85 |
| 2008 | 87 |
| 2009 | 47 |
| 2010 | 363 |
| 2011 | 185 |
| 2012 | 128 |
| 2013 | 82 |
| 2014 | 67 |
| 2015 | 127 |
| 2016 | 180 |
| 2017 | 206 |
| 2018 | 139 |
| 2019 | 184 |
| 2020 | 141 |
| 2021 | 118 |
| 2022 | 99 |
| 2023 | 91 |
| 2024 | 101 |
| 2025 | 74 |
| 2026 | 67 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erectile dysfunction.
Khera M, Goldstein I · BMJ Clin Evid 2011 · Systematic Review
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, do Carmo Novaes F, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for Buerger's disease.
Cacione DG, Baptista-Silva JC, Macedo CR · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, Baptista-Silva JC · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Erectile dysfunction: a global review of intracavernosal injectables.
Duncan C, Omran GJ, Teh J, et al. · World J Urol 2019 · Systematic Review
- MUSE therapy: preliminary clinical observations.
Werthman P, Rajfer J · Urology 1997 · Clinical Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.